BriaCell Therapeutics
BCTXPhase 3BriaCell is a clinical-stage biotechnology company developing innovative targeted immunotherapy treatments for cancer. Learn more about our cutting-edge research.
Market Cap
$30.3M
Focus
BiologicsDiagnosticsSmall Molecules
About
BriaCell is a clinical-stage biotechnology company developing innovative targeted immunotherapy treatments for cancer. Learn more about our cutting-edge research.
Pipeline Snapshot
44 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| SV-BR-1-GM + Cyclophosphamide + Interferon infiltration of the inoculation site ... | Breast Cancer | Phase 3 |
| SV-BR-1-GM + Low dose cyclophosphamide + Interferon Inoculation + retifanlimab | Breast Cancer | Phase 1/2 |
| BC1 cell line + Bria-OTS regimen and CPI (tislelizumab) + Bria-OTS regimen and C... | Breast Cancer | Phase 1/2 |
| SV-BR-1-GM + Cyclophosphamide + Interferon-alpha-2b | Breastcancer | Phase 1/2 |
Company Info
TypePublic
LocationUnited States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile